Invivyd Q4 2024 Earnings Report

Invivyd EPS Results

• Actual EPS: -$0.15
• Consensus EPS: -$0.25
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: N/A

Invivyd Revenue Results

• Actual Revenue: $13.80 million
• Expected Revenue: $13.57 million
• Beat/Miss: Beat by +$233.00 thousand
• YoY Revenue Growth: N/A

Invivyd Announcement Details

• Quarter: Q4 2024
• Date: 3/20/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, March 20, 2025
• Conference Call Time: 8:00AM ET

Invivyd (NASDAQ:IVVD) (NASDAQ: IVVD) is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with immune and autoimmune disorders. The company’s lead program is a high‐concentration subcutaneous immunoglobulin product designed to address primary immunodeficiency (PID) by offering more convenient administration and potentially fewer infusion‐related reactions compared to existing intravenous and subcutaneous formulations. Invivyd’s research and development efforts encompass both product optimization to enhance patient experience and expansion of its portfolio into other immunological indications.

Invivyd operates a GMP‐compliant manufacturing facility in New Jersey and maintains research laboratories in the greater Boston area to support its clinical and preclinical initiatives. The company’s production platform leverages advanced fractionation and purification technologies to deliver high‐purity immunoglobulin preparations at increased concentrations, enabling reduced infusion volumes and shorter administration times. Invivyd has also established strategic partnerships with contract manufacturing organizations in Europe to ensure global supply chain resilience and to facilitate potential future launches in international markets.

Founded in 2018 by a team of industry veterans and scientific leaders, Invivyd has assembled a seasoned leadership group to guide its clinical development and regulatory strategy. Chief Executive Officer John Simard brings more than two decades of experience in specialty pharmaceuticals, while Chief Scientific Officer Dr. Emily Chen has led immunoglobulin research programs at multiple biotech firms. The company’s board includes experts in immunology, neurology and rare diseases, reflecting Invivyd’s ambition to broaden its pipeline into conditions such as chronic inflammatory demyelinating polyneuropathy and certain autoimmune neurologic disorders.

With its headquarters in Cambridge, Massachusetts, and operations extending to the United States and Europe, Invivyd is positioning itself to meet the unmet needs of patients who require lifelong immunoglobulin replacement therapy. By focusing on patient‐centric product design and leveraging a robust manufacturing footprint, the company aims to deliver differentiated therapies that improve both clinical outcomes and quality of life for individuals living with immune deficiencies and related conditions.